This trial is testing a new medication for people with moderate to severe eczema. The study is double-blind, meaning neither the participants nor the researchers will know who is receiving the medication or the placebo.
- Atopic Dermatitis
0 Primary · 11 Secondary · Reporting Duration: Week 36
4 Treatment Groups
SCD-044 Tablets_Dose 1
1 of 4
SCD-044 Tablets_Dose 2
1 of 4
SCD-044 Tablets_Dose 3
1 of 4
Placebo of SCD-044 product
1 of 4
240 Total Participants · 4 Treatment Groups
Primary Treatment: SCD-044 Tablets_Dose 1 · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has recruitment for this clinical experiment already begun?
"Affirmative. According to clinicaltrials.gov, this study is actively recruiting; it was first announced on July 30th 2021 and most recently modified on August 26th 2022. The research aims at enrolling 240 participants from 17 separate medical centres." - Anonymous Online Contributor
How many individuals are partaking in this investigation?
"Affirmative. According to the records found on clinicaltrials.gov, this research trial is still actively recruiting participants and has been since July 30th 2021. The study requires 240 people from 17 different sites for admission." - Anonymous Online Contributor
How many healthcare centers are conducting this research study within the state's border?
"This clinical trial is operating at 17 sites, which include Site #08 in West Lafayette, Site #12 in Encino and Site #16 in Arlington. The remaining fourteen locations are also included." - Anonymous Online Contributor
Are there any adverse effects associated with SCD-044 Tablets_Dose 1?
"Our team at Power deem SCD-044 Tablets_Dose 1 to be a moderately safe medication, assigning it a score of 2. This evaluation is based on the fact that this is currently in Phase 2, which implies there are some safety data but none for efficacy." - Anonymous Online Contributor